House Bill 820 would require North Carolina health benefit plans that already cover prescription eye drops to also cover early refills under specified conditions. For a 30-day supply, a refill could not be denied if the patient requests it after enough time has passed that the patient should have used 70% of the medication according to the prescriber’s instructions, or after 21 days from the original fill or most recent refill, whichever applies. The refill also must remain within any refill limits set by the prescribing health care provider.
The bill also extends this mandate to the State Health Plan by incorporating the new eye-drop refill coverage requirement into the statutes governing that plan. It includes an appropriation of $100,000 in recurring General Fund money for each year of the 2025-2027 biennium to the Department of State Treasurer to cover the cost of the State Health Plan mandate. The private-plan coverage requirement would take effect October 1, 2025, and apply to new, renewed, or amended contracts on or after that date, while the State Health Plan change would apply at the start of the next plan year after that date.
HB820 would amend Chapter 58 of the General Statutes by creating a new insurance coverage mandate for early refills of prescription eye drops and by making that mandate applicable to the State Health Plan through G.S. 135-48.51. The bill would affect insurers offering health benefit plans in North Carolina, as well as the State Health Plan and the Department of State Treasurer, which would receive recurring appropriations to implement the coverage requirement. It would not broadly change prescription drug law, but it would add a specific consumer-protection style coverage rule for ophthalmic medications.
The available legislative record shows limited direct debate or recorded votes, so overall sentiment cannot be measured from committee remarks. The bill’s structure suggests a generally supportive policy goal of preventing coverage denials when patients need early access to eye-drop medication, and its referral to Appropriations indicates attention to the fiscal impact on the State Health Plan. The absence of recorded opposition in the provided materials leaves the public sentiment unclear, though the bill appears to have advanced at least to a re-referral to Appropriations.
The main point of contention is likely cost and administrative burden, especially for the State Health Plan and insurers that would have to adjust claims processing to allow early refills under the new standard. Another possible issue is the medical-necessity threshold, since the bill uses a 70% usage benchmark or a 21-day waiting period, which may be viewed as either a reasonable safeguard against waste or an insufficiently flexible rule for different treatment regimens. The bill also preserves prescriber refill limits, which may reduce concern about overuse but could still raise questions about how insurers verify compliance.